William Blair initiated coverage of Insmed (INSM) with an Outperform rating. The firm believes that clinical and commercial execution with Brinsupri, Arikayce, and TPIP have the potential to significantly increase Insmed’s valuation. The firm added that it believes the potential for a strong commercial launch of Brinsupri in the multi-blockbuster bronchiectasis indication will keep Insmed as a “must-own” name for investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Growth Potential: Buy Rating Backed by Strong Clinical Execution and Market Expansion Opportunities
- GS, BAC, LEN: Billionaire Investor Stanley Druckenmiller Buys Bank and Housing Stocks
- Insmed price target raised to $145 from $121 at Stifel
- Insmed price target raised to $139 from $126 at Truist
- H.C. Wainwright doubles Insmed target to $240 on ‘pipeline-in-a-pill’ potential